Profibrotic role of myostatin in peyronie's disease

Journal of Sexual Medicine

Volumn 5, Issue 7, 2008, Pages 1607-1622

  Cantini, Liliana P ^a,d   Ferrini, Monica G ^a,b,c   Vernet, Dolores ^a   Magee, Thomas R ^a,b   Qian, Ansha ^a   Gelfand, Robert A ^a   Rajfer, Jacob ^a,b   Gonzalez Cadavid, Nestor F ^a,b,c  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^d INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

Author keywords

Fibroblasts; Fibrosis; Myofibroblasts; Penis; Stem cells; TGF 1

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; COMPLEMENTARY DNA; MYOSTATIN; SHORT HAIRPIN RNA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL CULTURE; CELL DIFFERENTIATION; COLLAGEN DEFECT; CONTROLLED STUDY; FIBROGENESIS; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MALE; MYOFIBROBLAST; NONHUMAN; PENILE FIBROSIS; PEYRONIE DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RIBONUCLEASE PROTECTION ASSAY; TUNICA ALBUGINEA; UPREGULATION; WESTERN BLOTTING;

EID: 47949089084     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2008.00847.x     Document Type: Article

References (55)

1. Schwartz EJ, Wong P, Graydon RJ. Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. J Urol 2004; 171: 771-4.
2. Iacono F, Giannella R, Somma P, Manno G, Fusco F, Mirone V. Histological alterations in cavernous tissue after radical prostatectomy. J Urol 2005; 173: 1673-6.
3. Nandipati KC, Raina R, Agarwal A, Zippe CD. Erectile dysfunction following radical retropubic prostatectomy: Epidemiology, pathophysiology and pharmacological management. Drugs Aging 2006; 23: 101-17.
4. Ostojic P, Damjanov N. The impact of depression, microvasculopathy, and fibrosis on development of erectile dysfunction in men with systemic sclerosis. Clin Rheumatol 2007; 26: 1671-4.
5. Kovanecz I, Rambhatla A, Ferrini M, Vernet D, Sanchez S, Rajfer J, Gonzalez-Cadavid N. Long-term continuous sildenafil treatment ameliorates corporal veno-occlusive dysfunction (CVOD) induced by cavernosal nerve resection in rats. Int J Impot Res 2007 [Epub ahead of print].
6. Burnett AL. Molecular pharmacotherapeutic targeting of PDE5 for preservation of penile health. J Androl 2008; 29: 3-14.
7. Collado A, Batista E, Gelabert-Mas A, Corominas JM, Arano P, Villavicencio H. Detrusor quantitative morphometry in obstructed males and controls. J Urol 2006; 176: 2722-8.
8. Tuygun C, Imamoglu A, Keyik B, Alisir I, Yorubulut M. Significance of fibrosis around and/or at external urinary sphincter on pelvic magnetic resonance imaging in patients with postprostatectomy incontinence. Urology 2006; 68: 1308-12.
9. Bercovich E, Barabino G, Pirozzi-Farina F, Deriu M. A multivariate analysis of lower urinary tract ageing and urinary symptoms: The role of fibrosis. Arch Ital Urol Androl 1999; 71: 287-92.
10. Liu Y. Renal fibrosis: New insights into the pathogenesis and therapeutics. Kidney Int 2006; 69: 213-7.
11. Eberhardt W, Pfeilschifter J. Nitric oxide and vascular remodeling: Spotlight on the kidney. Kidney Int Suppl 2007; S9-16.
12. Bella AJ, Perelman MA, Brant WO, Lue TF. Peyronie's disease (CME). J Sex Med 2007; 4: 1527-38.
13. Gonzalez-Cadavid NF, Rajfer J. Mechanisms of disease: New insights into the cellular and molecular pathology of Peyronie's disease. Nat Clin Pract Urol 2005; 2: 291-8.
14. Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J. TGF-beta signaling in vascular fibrosis. Cardiovasc Res 2007; 74: 196-206.
15. El-Sakka AI, Hassoba HM, Pillarisetty RJ, Dahiya R, Lue TF. Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 1997; 158: 1391-4.
16. Darby IA, Hewitson TD. Fibroblast differentiation in wound healing and fibrosis. Int Rev Cytol 2007; 257: 143-79.
17. Henderson NC, Iredale JP. Liver fibrosis: Cellular mechanisms of progression and resolution. Clin Sci (Lond) 2007; 112: 265-80.
18. El-Sakka AI, Hassan MU, Nunes L, Bhatnagar RS, Yen TS, Lue TF. Histological and ultrastructural alterations in an animal model of PD disease. Br J Urol 1998; 81: 445-52.
19. Ferrini MG, Vernet D, Magee TR, Shahed A, Qian A, Rajfer J, Gonzalez-Cadavid NF. Antifibrotic role of inducible nitric oxide synthase. Nitric Oxide 2002; 6: 283-94.
20. Vernet D, Ferrini MG, Valente EG, Magee TR, Bou-Gharios G, Rajfer J, Gonzalez-Cadavid NF. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's disease fibrotic plaque and in its rat model. Nitric Oxide 2002; 7: 262-76.
21. Ferrini MG, Kovanecz I, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. BJU Int 2006; 97: 625-33.
22. Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's disease fibrotic plaque and related fibroblast cultures. Nitric Oxide 2003; 9: 229-44.
23. Davila HH, Magee TR, Zuniga FI, Rajfer J, Gonzalez-Cadavid NF. Peyronie's disease associated with increase in plasminogen activator inhibitor in fibrotic plaque. Urology 2005; 65: 645-8.
24. Davila HH, Ferrini MG, Rajfer J, Gonzalez-Cadavid NF. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: A new animal model of Peyronie's disease. BJU Int 2003; 91: 830-8.
25. Davila HH, Magee TR, Vernet D, Rajfer J, Gonzalez-Cadavid NF. Gene transfer of inducible nitric oxide synthase complementary DNA regresses the fibrotic plaque in an animal model of Peyronie's disease. Biol Reprod 2004; 71: 1568-77.
26. Tsuchida K. Activins, myostatin and related TGF-beta family members as novel therapeutic targets for endocrine, metabolic and immune disorders. Curr Drug Targets Immune Endocr Metabol Disord 2004; 4: 157-66.
27. Wang W, Koka V, Lan HY. Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology (Carlton) 2005; 10: 48-56.
28. Fan J, Shen H, Sun Y, Li P, Burczynski F, Namaka M, Gong Y. Bone morphogenetic protein 4 mediates bile duct ligation induced liver fibrosis through activation of Smad1 and ERK1/2 in rat hepatic stellate cells. J Cell Physiol 2006; 207: 499-505.
29. Parsons CJ, Takashima M, Rippe RA. Molecular mechanisms of hepatic fibrogenesis. J Gastroenterol Hepatol 2007; 22 (1 suppl): S79-84.
30. Lee SJ. Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol 2004; 20: 61-86.
31. Gonzalez-Cadavid NF, Taylor WE, Yarasheski K, Sinha-Hikim I, Ma K, Ezzat S, Shen R, Lalani R, Asa S, Mamita M, Nair G, Arver S, Bhasin S. Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc Natl Acad Sci USA 1998; 95: 14938-43.
32. Gonzalez-Cadavid NF, Bhasin S. Role of myostatin in metabolism. Curr Opin Clin Nutr Metab Care 2004; 7: 451-7.
33. Wagner KR, McPherron AC, Winik N, Lee SJ. Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol 2002; 52: 832-6.
34. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, Khurana TS. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002; 420: 418-21.
35. McCroskery S, Thomas M, Platt L, Hennebry A, Nishimura T, McLeay L, Sharma M, Kambadur R. Improved muscle healing through enhanced regeneration and reduced fibrosis in myostatin-null mice. J Cell Sci 2005; 118: 3531-41.
36. Zhu J, Li Y, Shen W, Qiao C, Ambrosio F, Lavasani M, Nozaki M, Branca MF, Huard J. Relationships between transforming growth factor-beta1, myostatin, and decorin: Implications for skeletal muscle fibrosis. J Biol Chem 2007; 282: 25852-63.
37. Artaza J, Singh R, Ferrini MG, Braga M, Tsao J, Gonzalez-Cadavid NF. Myostatin promotes a fibrotic phenotypic switch in multipotent C3H 10T1/ 2 cells without affecting their differentiation into myofibroblasts. J Endocrinol 2008; 196: 235-49.
38. Artaza JN, Bhasin S, Magee TR, Reisz-Porszasz S, Shen R, Groome NP, Meerasahib MF, Gonzalez-Cadavid NF. Myostatin inhibits myogenesis and promotes adipogenesis in C3H 10T(1/2) mesenchymal multipotent cells. Endocrinology 2005; 146: 3547-57.
39. Taylor WE, Bhasin S, Artaza J, Byhower F, Azam M, Willard DH Jr, Kull FC Jr, Gonzalez-Cadavid N. Myostatin inhibits cell proliferation and protein synthesis in C2C12 muscle cells. Am J Physiol Endocrinol Metab 2001; 280: E221 -8.
40. Magee TR, Artaza JN, Ferrini MG, Zuniga FI, Cantini L, Reisz-Porszasz S, Rajfer J, Gonzalez-Cadavid NF. Myostatin short interfering hairpin RNA gene transfer increases skeletal muscle mass. J Gene Med 2006; 9: 1171-81.
41. Vernet D, Nolazco G, Cantini L, Magee TR, Qian A, Rajfer J, Gonzalez-Cadavid NF. Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: Implications for Peyronie's disease. Biol Reprod 2005; 73: 1199-210.
42. Qian A, Meals RA, Rajfer J, Gonzalez-Cadavid NF. Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture. Urology 2004; 64: 399-404.
43. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. Multilineage cells from human adipose tissue: Implications for cell-based therapies. Tissue Eng 2001; 7: 211-28.
44. Calzone FJ, Britten RJ, Davidson EH. Mapping of gene transcripts by nuclease protection assays and cDNA primer extension. Methods Enzymol 1987; 152: 611-32.
45. Nolazco G, Kovanecz I, Vernet D, Ferrini M, Gelfand B, Tsao J, Magee T, Rajfer J, Gonzalez-Cadavid NF. Effect of muscle derived stem cells on the restoration of corpora cavernosa smooth muscle and erectile function in the aged rat. BJU Int 2008 Feb 21; [Epub ahead of print].
46. Artaza JN, Reisz-Porszasz S, Dow JS, Kloner RA, Tsao J, Bhasin S, Gonzalez-Cadavid NF. Alterations in myostatin expression are associated with changes in cardiac left ventricular mass but not ejection fraction in the mouse. J Endocrinol 2007; 194: 63-76.
47. Li Y, Foster W, Deasy BM, Chan Y, Prisk V, Tang Y, Cummins J, Huard J. Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: A key event in muscle fibrogenesis. Am J Pathol 2004; 164: 1007-19.
48. Amthor H, Nicholas G, McKinnell I, Kemp CF, Sharma M, Kambadur R, Patel K. Follistatin complexes myostatin and antagonises myostatin-mediated inhibition of myogenesis. Dev Biol 2004; 270: 19-30.
49. Aoki F, Kurabayashi M, Hasegawa Y, Kojima I. Attenuation of bleomycin-induced pulmonary fibrosis by follistatin. Am J Respir Crit Care Med 2005; 172: 713-20.
50. Yamanaka O, Ikeda K, Saika S, Miyazaki K, Ooshima A, Ohnishi Y. Gene transfer of Smad7 modulates injury-induced conjunctival wound healing in mice. Mol Vis 2006; 12: 841-51.
51. Liu X, Sun SQ, Hassid A, Ostrom RS. cAMP inhibits transforming growth factor-beta-stimulated collagen synthesis via inhibition of extracellular signal-regulated kinase 1/2 and Smad signaling in cardiac fibroblasts. Mol Pharmacol 2006; 70: 1992-2003.
52. Gressner OA, Weiskirchen R, Gressner AM. Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options. Comp Hepatol 2007; 6: 7.
53. Sugimoto H, Grahovac G, Zeisberg M, Kalluri R. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes 2007; 56: 1825-33.
54. Izumi N, Mizuguchi S, Inagaki Y, Saika S, Kawada N, Nakajima Y, Inoue K, Suehiro S, Friedman SL, Ikeda K. BMP-7 opposes TGF-beta1-mediated collagen induction in mouse pulmonary myofibroblasts through Id2. Am J Physiol Lung Cell Mol Physiol 2006; 290: L120 -6.
55. Qi W, Chen X, Twigg S, Zhang Y, Gilbert RE, Kelly DJ, Pollock CA. The differential regulation of Smad7 in kidney tubule cells by connective tissue growth factor and transforming growth factor-beta1. Nephrology (Carlton) 2007; 12: 267-74.